Cladribine is an antimetabolite used for the treatment of relapsing–remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk.
Objective:
We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose.
Methods:
Analysis was done using liquid chromatography–mass spectrometry.
Results:
The relative infant dose calculated in this study was 3.06%.
Conclusion:
This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.
HermannRKarlssonMONovakovicAM, et al. Correction to: The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet2019; 58: 283–297.
2.
TroussardXCornetE.Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol2017; 92: 1382–1390.
3.
BostromIStawiarzLLandtblomAM.Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). Mult Scler2013; 19: 46–52.
4.
OrtonSMHerreraBMYeeIM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol2006; 5: 932–936.
ScheibleHLaisneyMWimmerE, et al. Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica2013; 43: 1084–1094.
